Cesca Therapeutics (NASDAQ:KOOL) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
According to Zacks, “Cesca Therapeutics Inc. is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It also develops and manufactures automated blood and bone marrow processing systems and companion disposable products that enable the separation, processing and preservation of cell and tissue therapy products. The Company sells its products in approximately 30 countries throughout the world to customers that include private and public cord blood banks, surgeons, hospitals and research institutions. Cesca Therapeutics Inc., formerly known as ThermoGenesis Corp., is headquartered in Rancho Cordova, California. “
Separately, ValuEngine raised shares of Cesca Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 4th.
Cesca Therapeutics (NASDAQ:KOOL) last released its quarterly earnings data on Monday, August 13th. The biotechnology company reported $0.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.16. The business had revenue of $2.00 million for the quarter, compared to the consensus estimate of $3.00 million. Cesca Therapeutics had a negative net margin of 322.75% and a negative return on equity of 18.05%. On average, analysts anticipate that Cesca Therapeutics will post 0.1 earnings per share for the current fiscal year.
About Cesca Therapeutics
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.